| nivolumab based treatment | pembrolizumab alone | pembrolizumab based treatment |
| nivolumab alone | pembrolizumab (10mg/kg) | pembrolizumab (10mg/kg) 2 weeks | pembrolizumab (2mg/kg) | pembrolizumab plus SoC |
| mML - 2nd line (L2) | | | | | |
| mML - L2 - all population 11 | | | | | |
| mML - L2 - BRAF mutant 1 | | | | | |
Comparator:
vs Standard of Care (SoC); vs ipilimumab alone; vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;